In a report released today, Steve Beuchaw from Morgan Stanley maintained a Buy rating on PerkinElmer (NYSE: PKI), with a price target of $100. The company’s shares closed yesterday at $90.75.
According to TipRanks.com, Beuchaw is a 4-star analyst with an average return of 12.6% and a 64.6% success rate. Beuchaw covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Myriad Genetics, and NanoString Tech.
The word on The Street in general, suggests a Hold analyst consensus rating for PerkinElmer with a $91.33 average price target.
See today’s analyst top recommended stocks >>
PerkinElmer’s market cap is currently $10.05B and has a P/E ratio of 68.72. The company has a Price to Book ratio of 3.99.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock. Most recently, in August 2018, Patrick Sullivan, a Director at PKI sold 12,672 shares for a total of $1,092,200.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PerkinElmer, Inc. (United States) engages in the provision of products, services, and solutions to diagnostics, food, environmental, industrial, life sciences research, and laboratory services markets. It operates through the Discovery and Analytical Solutions, and Diagnostics segments.
